Alzeca Biosciences

Alzeca Biosciences is developing a proprietary imaging agent to diagnose Alzheimer's Disease at the earliest stages.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Founded January 2011
  • Employees 6
  • Website alzeca.com

Company Summary

Alzeca Biosciences is developing ADx, an imaging agent used to detect early stage Alzheimer's Disease. Alzeca's primary goal is to diagnose Alzheimer's early enough, where lifestyle changes (diet, exercise) and therapeutics can still be beneficial. A second benefit of the ADx platform is to more effectively monitor the effectiveness of therapies under development, while enabling more accurate screening of Alzheimer's patients in drug trials.

Team

  • Robin Mansukhani
    CEO

    Previous venture capital, I Banking, and start-up biotech experience. Frequent speaker on entrepreneurship, life sciences, and education (including TED). B.S. in Biochemistry from Case Western Reserve University.

  • Ananth Annapragada
    Chief Scientific Advisor

    Director of Radiology, Texas Children's Hospital in Houston. Serial entrepreneur with 3 previous start-ups spun out from his lab. >$35M raised for previous start-ups.

  • Jason Eriksen
    Chief Technical Officer

    Co-inventor of Alzeca technology. Ph.D in Neuroscience and previous drug development experience. Post doc from Mayo Clinic.

  • Steve Cook
    Board Member

    CEO, Fieldstone Partners -- Houston based merchant bank. MBA, Harvard University.

  • Robin Mansukhani

Advisors

  • Ewing & Jones, Benesch Friedlander
    Lawyer
    Unconfirmed
    N/A
    Accountant
    Unconfirmed

Previous Investors

  • Central Texas Angel Network, Fieldstone Partners
    Unconfirmed
    Angel Investors, Non dilutive government and foundation grants
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free